Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the creation of a direct financial obligation. The report date is January 29, 2021, and the filing was signed February 3, 2021. The obligation relates to financing for development of the LUNAR-COV19 vaccine candidate.
Key Financial Terms and Metrics
- The Economic Development Board of the Republic of Singapore agreed to provide a term loan of up to $45.0 million, subject to exchange-rate adjustments and customary conditions.
- Arcturus drew the full available amount on January 29, 2021. Due to exchange rates, $46.5 million was funded.
- The filing does not provide revenue, profit, cash flow, margin, or broader liquidity metrics.
- The loan is generally limited recourse and is intended to be repaid through royalty payments based on sales of LUNAR-COV19, with a portion of vaccine-sale proceeds applied quarterly to outstanding principal and interest.
Material Changes and Terms
- The $46.5 million funding created a new direct financial obligation for the company.
- All unpaid principal and interest become due five years after the draw date if vaccine net sales exceed a specified minimum threshold during that period or if the company receives clearance to sell the vaccine in specified jurisdictions.
- Amounts also become due upon an event of default under the Manufacturing Support Agreement.
- If any portion of the loan is required to be forgiven, the EDB may take ownership of certain raw materials and equipment purchased with loan proceeds.
- The company granted the EDB a security interest in specified assets to secure repayment and related obligations.
Outlook, Risks, Contingencies, and Unusual Items
The financing is tied to the development and potential commercialization of LUNAR-COV19. Repayment depends substantially on vaccine sales and royalty economics, while specified sales, regulatory-clearance, and default events can accelerate repayment. The filing does not provide updated development timelines, regulatory status, sales forecasts, or management guidance.
Important Facts to Verify
- The complete Manufacturing Support Agreement and related security agreement, including the exact royalty rate, repayment mechanics, minimum sales threshold, specified jurisdictions, covenants, and events of default.
- Whether the loan was recorded as debt at funding and the applicable interest rate and accounting treatment.
- The carrying value and identity of assets subject to the EDB lien.
- The current development, regulatory, and commercialization status of LUNAR-COV19.
- Any subsequent disclosures regarding repayment, forgiveness, amendments, defaults, or acceleration of the loan.